Highlights:

  • Xenitra signed a three-year Framework Purchase Agreement for Food for Special Medical Purposes products with JOY CHARM LIMITED.
  • The agreement establishes a target aggregate procurement value of A$5 million over three years.
  • The deal expands Fukang’s healthcare offering beyond traditional over-the-counter medicines into specialised medical nutrition.
  • Fukang recorded July sales of more than $450k AUD following its Acquisition and post-merger integration.
  • The agreement follows Xenitra’s previously announced A$12 million pharmaceutical procurement agreement with Kangsheng.

Xenitra Limited (ASX:XEN) has expanded its healthcare platform after its Hong Kong Subsidiary Hong Kong Fukang Trade Limited signed a three-year Framework Purchase Agreement with JOY CHARM LIMITED for Food for Special Medical Purposes (FSMP) products.

Xenitra was trading at AUD 0.0030, unchanged at the time of writing on 18 August 2026. The latest agreement adds another commercial arrangement to the recently acquired Fukang business, extending its healthcare offering into specialised medical nutrition alongside its existing pharmaceutical and nutrition-related activities.

Fukang Adds New Healthcare Procurement Agreement

Under the agreement, Joy Charm has committed to a target aggregate procurement value of A$5 million over the three-year period from 12 August 2026 to 12 August 2029.

The agreement covers the Supply of FSMP products, with specific products, quantities, pricing and delivery schedules to be determined through individual purchase orders.

Payment terms provide for 20% of each purchase order value to be paid within seven days following execution and receipt of invoice. The remaining 80% is payable within seven days after receipt of required commercial and shipping documentation, subject to agreed delivery arrangements.

Xenitra stated that the structure provides Working Capital terms aligned with the company’s broader over-the-counter medicine operations.

Healthcare Expansion Beyond Traditional OTC Medicines

The agreement represents a further development of Fukang’s commercial pipeline following its acquisition by Xenitra earlier this year.

The company said the agreement broadens Fukang’s activities beyond conventional over-the-counter medicines into specialised medical nutrition products, while using existing sourcing, regulatory, logistics and commercial capabilities.

The new agreement follows Xenitra’s previously announced A$12 million three-year pharmaceutical procurement agreement with Kangsheng.

Together, these agreements expand Fukang’s role within Xenitra’s healthcare strategy, which also includes nutritionals and the OPAL real-world asset (RWA) tokenised sales platform.

Non-Executive Chairman Dr Anthony Noble said the latest agreement and the Kangsheng arrangement represent further steps in developing Fukang’s commercial pipeline.

Fukang Records Early Sales Growth After Acquisition

Xenitra highlighted that Fukang achieved sales of more than $450k AUD during July following its acquisition and post-merger integration in June.

The company stated that Fukang is being developed as a broader healthcare platform rather than operating as a standalone business, with opportunities across pharmaceutical products, specialised nutrition and other regulated healthcare categories.

The company’s strategy involves combining Fukang’s healthcare capabilities with Xenitra’s existing nutritionals Business and OPAL platform.

FSMP Market Provides Additional Healthcare Focus

Xenitra’s latest agreement targets the Food for Special Medical Purposes market in China.

According to company-provided market data, China’s FSMP market increased from approximately RMB7 billion (A$1.5 billion) in 2020 to RMB23 billion (A$4.8 billion) in 2024, representing annualised growth of more than 25%.

The company also noted that imported FSMP products remain an important part of the market, with national FSMP Import values increasing by approximately 50% between 2021 and 2023.

From 2024, China reduced import tariffs to zero for FSMP products intended for people aged over three years, extending existing zero-tariff treatment for infant FSMP products.

Commercial Pipeline Expands Across Healthcare Segments

Xenitra continues to develop its healthcare ecosystem across FMCG, nutraceuticals, over-the-counter medicines and personal care products.

The company said Fukang provides access to sourcing, regulatory and distribution capabilities that can support additional healthcare products and counterparties.

The Joy Charm agreement establishes a potential sales pathway over the next three years, although purchases remain subject to individual purchase orders and the A$5 million procurement amount represents a target rather than a guaranteed minimum commitment.

The company is also continuing to develop its OTC medicines opportunity in China, where it highlighted an established pharmacy market and expanding online medicine distribution channels.

Strategic Focus on Asian Sales Ecosystem

Xenitra’s broader business model incorporates business-to-business trading, retail distribution and ecommerce channels across China and Australia.

The company stated that its OPAL ecosystem integrates blockchain-enabled tokenised distribution channels with mainstream FMCG sales activities.

With the addition of Fukang, Xenitra is seeking to build multiple commercial pathways across healthcare, nutritionals and digital-enabled sales channels.

Investor Takeaway

Xenitra’s latest announcement adds another procurement agreement to the Fukang healthcare platform, expanding its product focus into specialised medical nutrition. Investors may continue watching the execution of the Joy Charm agreement, development of Fukang’s sales pipeline, progress of the Kangsheng pharmaceutical agreement and the company’s broader healthcare and nutrition strategies.